Literature DB >> 26076126

Early recovery of CMV immunity after HLA-haploidentical hematopoietic stem cell transplantation as a surrogate biomarker for a reduced risk of severe infections overall.

M Noviello1, A Forcina2,3, V Veronica4, R Crocchiolo5, M T L Stanghellini2, M Carrabba2, R Greco2, L Vago2,6, F Giglio2, A Assanelli2, M R Carbone1, Z Magnani1, F Crippa7, C Corti2, M Bernardi2, J Peccatori2, C Bordignon3,4, F Ciceri2, C Bonini1, A Bondanza3,8.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 26076126     DOI： 10.1038/bmt.2015.132

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  15 in total

1.  Competing risk analysis using R: an easy guide for clinicians.

Authors:  L Scrucca; A Santucci; F Aversa
Journal:  Bone Marrow Transplant       Date:  2007-06-11       Impact factor: 5.483

2.  Evaluation of cytomegalovirus-specific T-cell reconstitution in patients after various allogeneic haematopoietic stem cell transplantation using interferon-gamma-enzyme-linked immunospot and human leucocyte antigen tetramer assays with an immunodominant T-cell epitope.

Authors:  Mutsuko Ohnishi; Toshiharu Sakurai; Yuji Heike; Rie Yamazaki; Yoshinobu Kanda; Yoichi Takaue; Hideaki Mizoguchi; Yutaka Kawakami
Journal:  Br J Haematol       Date:  2005-11       Impact factor: 6.998

3.  CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia.

Authors:  Margaret L Green; Wendy M Leisenring; Hu Xie; Roland B Walter; Marco Mielcarek; Brenda M Sandmaier; Stanley R Riddell; Michael Boeckh
Journal:  Blood       Date:  2013-06-06       Impact factor: 22.113

4.  Human cytomegalovirus (CMV)-induced memory-like NKG2C(+) NK cells are transplantable and expand in vivo in response to recipient CMV antigen.

Authors:  Bree Foley; Sarah Cooley; Michael R Verneris; Julie Curtsinger; Xianghua Luo; Edmund K Waller; Claudio Anasetti; Daniel Weisdorf; Jeffrey S Miller
Journal:  J Immunol       Date:  2012-10-17       Impact factor: 5.422

5.  Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study.

Authors:  Fabio Ciceri; Chiara Bonini; Maria Teresa Lupo Stanghellini; Attilio Bondanza; Catia Traversari; Monica Salomoni; Lucia Turchetto; Scialini Colombi; Massimo Bernardi; Jacopo Peccatori; Alessandra Pescarollo; Paolo Servida; Zulma Magnani; Serena K Perna; Veronica Valtolina; Fulvio Crippa; Luciano Callegaro; Elena Spoldi; Roberto Crocchiolo; Katharina Fleischhauer; Maurilio Ponzoni; Luca Vago; Silvano Rossini; Armando Santoro; Elisabetta Todisco; Jane Apperley; Eduardo Olavarria; Shimon Slavin; Eva M Weissinger; Arnold Ganser; Michael Stadler; Evangelia Yannaki; Athanasios Fassas; Achilles Anagnostopoulos; Marco Bregni; Corrado Gallo Stampino; Paolo Bruzzi; Claudio Bordignon
Journal:  Lancet Oncol       Date:  2009-04-01       Impact factor: 41.316

6.  Factors influencing cytomegalovirus seropositivity in stem cell transplant patients and donors.

Authors:  Per Ljungman; Ronald Brandan
Journal:  Haematologica       Date:  2007-08       Impact factor: 9.941

7.  Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors.

Authors:  J Peccatori; A Forcina; D Clerici; R Crocchiolo; L Vago; M T L Stanghellini; M Noviello; C Messina; A Crotta; A Assanelli; S Marktel; S Olek; S Mastaglio; F Giglio; L Crucitti; A Lorusso; E Guggiari; F Lunghi; M Carrabba; M Tassara; M Battaglia; A Ferraro; M R Carbone; G Oliveira; M G Roncarolo; S Rossini; M Bernardi; C Corti; M Marcatti; F Patriarca; M Zecca; F Locatelli; C Bordignon; K Fleischhauer; A Bondanza; C Bonini; F Ciceri
Journal:  Leukemia       Date:  2014-06-04       Impact factor: 11.528

8.  γδT cells elicited by CMV reactivation after allo-SCT cross-recognize CMV and leukemia.

Authors:  W Scheper; S van Dorp; S Kersting; F Pietersma; C Lindemans; S Hol; S Heijhuurs; Z Sebestyen; C Gründer; V Marcu-Malina; A Marchant; C Donner; B Plachter; D Vermijlen; D van Baarle; J Kuball
Journal:  Leukemia       Date:  2013-01-01       Impact factor: 11.528

9.  Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects.

Authors:  Andrew W Sylwester; Bridget L Mitchell; John B Edgar; Cara Taormina; Christian Pelte; Franziska Ruchti; Paul R Sleath; Kenneth H Grabstein; Nancy A Hosken; Florian Kern; Jay A Nelson; Louis J Picker
Journal:  J Exp Med       Date:  2005-09-05       Impact factor: 14.307

10.  Human cytomegalovirus drives epigenetic imprinting of the IFNG locus in NKG2Chi natural killer cells.

Authors:  Merlin Luetke-Eversloh; Quirin Hammer; Pawel Durek; Karl Nordström; Gilles Gasparoni; Matthias Pink; Alf Hamann; Jörn Walter; Hyun-Dong Chang; Jun Dong; Chiara Romagnani
Journal:  PLoS Pathog       Date:  2014-10-16       Impact factor: 6.823
View more
  6 in total

1.  The patient's CMV serological status affects clinical outcome after T-cell replete haplo-HSCT and post-transplant cyclophosphamide.

Authors:  R Crocchiolo; L Castagna; S Furst; R Devillier; B Sarina; S Bramanti; J El-Cheikh; A Granata; S Harbi; L Morabito; C Faucher; A Rimondo; D Girardi; B Mohty; B Calmels; C Carlo-Stella; C Chabannon; R Bouabdallah; A Santoro; N Vey; P J Weiller; D Blaise
Journal:  Bone Marrow Transplant       Date:  2016-03-21       Impact factor: 5.483

Review 2.  CMV-specific immune reconstitution following allogeneic stem cell transplantation.

Authors:  Emily Blyth; Barbara Withers; Leighton Clancy; David Gottlieb
Journal:  Virulence       Date:  2016-08-09       Impact factor: 5.882

3.  Patient risk stratification and tailored clinical management of post-transplant CMV-, EBV-, and BKV-infections by monitoring virus-specific T-cell immunity.

Authors:  Anastasia Papadopoulou; Kiriakos Koukoulias; Maria Alvanou; Vassilios K Papadopoulos; Zoe Bousiou; Vasiliki Kalaitzidou; Fotini S Kika; Apostolia Papalexandri; Despina Mallouri; Ioannis Batsis; Ioanna Sakellari; Achilles Anagnostopoulos; Evangelia Yannaki
Journal:  EJHaem       Date:  2021-06-01

4.  T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromes.

Authors:  R Devillier; S Bramanti; S Fürst; B Sarina; J El-Cheikh; R Crocchiolo; A Granata; C Chabannon; L Morabito; S Harbi; C Faucher; A Santoro; P-J Weiller; N Vey; C Carlo-Stella; L Castagna; D Blaise
Journal:  Bone Marrow Transplant       Date:  2015-11-09       Impact factor: 5.483

5.  Immunologic monitoring of cytomegalovirus (CMV) enzyme-linked immune absorbent spot (ELISPOT) for controlling clinically significant CMV infection in pediatric allogeneic hematopoietic stem cell transplant recipients.

Authors:  Euri Seo; Eun Seok Choi; Jung Hwa Kim; Hyery Kim; Kyung-Nam Koh; Ho Joon Im; Jina Lee
Journal:  PLoS One       Date:  2021-02-05       Impact factor: 3.240

Review 6.  CMV Infection and CMV-Specific Immune Reconstitution Following Haploidentical Stem Cell Transplantation: An Update.

Authors:  Xiao-Hua Luo; Yan Zhu; Yu-Ting Chen; Li-Ping Shui; Lin Liu
Journal:  Front Immunol       Date:  2021-10-28       Impact factor: 7.561
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.